Inhaled iloprost for the treatment of pulmonary hypertension

European Respiratory Review

Volumn 18, Issue 111, 2009, Pages 29-34

  Olschewski, H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Clinical trials; Iloprost; Inhalation; Pulmonary hypertension; Review

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN;

ADD ON THERAPY; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; HUMAN; JAW DISEASE; MONOTHERAPY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TACHYPHYLAXIS; THROMBOSIS; VASOCONSTRICTION;

ADMINISTRATION, INHALATION; CLINICAL TRIALS AS TOPIC; HUMANS; ILOPROST; PULMONARY INFARCTION; VASODILATOR AGENTS;

EID: 61649096423     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00011111     Document Type: Article

References (28)

1. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891-901.
2. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
3. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:Suppl. 12, 5S-12S.
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
6. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
7. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med 2008; 21:1-12.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436.
9. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
10. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double- blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496-1502.
11. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342: 961-962.
12. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 991-996.
13. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824.
14. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132: 435-443.
15. Stricker H, Domenighetti G, Fiori G, Mombelli G. Sustained improvement of performance and haemody- namics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Schweiz Med Wochenschr 1999; 129: 923-927.
16. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-1870.
17. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld- Wollbruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998; 24: 631-634.
18. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600-607.
19. Dernaika TA, Beavin ML, Kinasewitz GT. Iloprost improves gas exchange in COPD patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: A443.
20. Krowka MJ, Ahmad S, de Andrade JA, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis. Chest 2007; 132: Suppl., 633S.
21. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
22. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
23. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. EurRespirJ2006; 28: 691-694.
24. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005; 26: 1895-1902.
25. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
26. Bayer Schering Pharma AG. Open-label, uncontrolled, long- term surveillance study of iloprost aerosol inhalation therapy in the treatment of patients with primary or secondary pulmonary hypertension. www. clinicalstudyresults.org/ drugdetails /?company-id=73&indication-id= 854&sort=c. company-name&page=1&drug-id=2423 Date last updated: May 2007. Date last accessed: December 16, 2008.
27. Olschewski H, Nikkho S, Behr J, et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost. Eur Heart J 2003; 24: 482 (abstract 2567).
28. Frost AE, the STEP investigators. STEP-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2007; 175: Suppl., A1001.